U.S. Induced Pluripotent Stem Cell (iPSC) Market is Booming with Promising CAGR of 9.6% Reaching Nearly USD 1,372.22 Million by 2032

𝐔.𝐒. 𝐈𝐧𝐝𝐮𝐜𝐞𝐝 𝐏𝐥𝐮𝐫𝐢𝐩𝐨𝐭𝐞𝐧𝐭 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 (𝐢𝐏𝐒𝐂) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐚𝐧𝐝 𝐬𝐡𝐚𝐫𝐞 𝐢𝐬 𝐜𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟔𝟎𝟒.𝟐𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 𝐚𝐧𝐝 𝐢𝐬 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐝 𝐭𝐨 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐚𝐧 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐨𝐟 𝐔𝐒𝐃 𝟏,𝟑𝟕𝟐.𝟐𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐚𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐬𝐭𝐮𝐝𝐲 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡. 𝐁𝐞𝐬𝐢𝐝𝐞𝐬, 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐧𝐨𝐭𝐞𝐬 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐬 𝐚 𝐫𝐨𝐛𝐮𝐬𝐭 𝟗.𝟔% 𝐂𝐨𝐦𝐩𝐨𝐮𝐧𝐝 𝐀𝐧𝐧𝐮𝐚𝐥 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐚𝐭𝐞 (𝐂𝐀𝐆𝐑) 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭𝐞𝐝 𝐭𝐢𝐦𝐞𝐟𝐫𝐚𝐦𝐞, 𝟐𝟎𝟐𝟒 - 𝟐𝟎𝟑𝟐

The U.S. Induced Pluripotent Stem Cell (iPSC) market is poised to witness rapid growth over the forecast period, according to the latest report by Polaris Market Research. The rising demand for personalized medicine and increasing research initiatives act as major driver propelling the expansion of the market.
The U.S. iPSC market is a dynamic sector within the broader field of regenerative medicine, focusing on the use of iPSCs for disease modeling, drug discovery, and cell therapy applications. iPSCs are reprogrammed adult cells that possess pluripotent characteristics, making them valuable tools for research and therapeutic development.

𝐂𝐥𝐢𝐜𝐤 𝐭𝐨 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐧𝐝 𝐃𝐫𝐢𝐯𝐞 𝐈𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬:
https://www.polarismarketresearch.com/industry-analysis/us-induced-pluripotent-stem-cell-ipsc-market/request-for-sample

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

The U.S. induced pluripotent stem cell (iPSC) market is rapidly evolving and highly dynamic. It has the presence of established players and emerging startups. Leading industry participants in the sector have invested heavily in research and development initiatives to garner a larger market share. Some of the major players operating in the industry include:

• Applied StemCell
• Astellas Pharma Inc.
• Catalent, Inc
• Evotec
• Fate Therapeutics
• FUJIFILM Holdings Corporation (Cellular Dynamics)
• REPROCELL Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• ViaCyte, Inc

𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐮𝐭𝐥𝐨𝐨𝐤

• The market size for U.S. Induced Pluripotent Stem Cell (iPSC) was valued at USD 604.22 million in 2023.
• The market is projected to grow to USD 1,372.22 million by 2032.
• The industry is anticipated to exhibit a CAGR of 9.6% during the forecast period from 2024 to 2032.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
https://www.polarismarketresearch.com/buy/3870/2

𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

Induced pluripotent stem cells (iPSC) refer to a stem cell type that can be generated from adult skin or blood cells. As with embryonic stem cells, these cells are known for their ability to differentiate into any cell type within the body. The discovery of iPSCs was a major achievement in the field of stem cell biology.
The pluripotent nature of these cells means that they hold immense potential for disease modeling, regenerative medicine, and drug discovery. Also, the versatility of these cells has led to widespread adoption in biomedical research. Furthermore, these cells can be prodded into becoming beta islet cells to treat diabetes and cardiovascular diseases.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬:

• 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐑𝐞𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐦𝐢𝐧𝐠 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬: Ongoing advancements in cellular reprogramming techniques, such as episomal vectors, synthetic mRNA, and small molecules, contribute to the efficiency and safety of iPSC generation, driving market growth.

•𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬: The rising prevalence of chronic diseases, such as neurodegenerative disorders, cardiovascular diseases, and diabetes, creates a demand for innovative therapies and personalized medicine approaches, fostering the development of iPSC-based treatments.

• 𝐒𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐯𝐞 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), provide guidance and support for the translation of iPSC-based therapies from preclinical research to clinical trials, facilitating market growth and investment in the field.

• 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Collaborations between academia, industry, and government entities drive innovation and accelerate the development of iPSC-based therapies, fostering a collaborative ecosystem conducive to market expansion.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:
https://www.polarismarketresearch.com/industry-analysis/us-induced-pluripotent-stem-cell-ipsc-market

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

• The market segmentation is primarily based on derived cell, workflow, and application.
• By workflow insights, the cell culture segment dominated the market owing to the crucial role they play in the production and maintenance of induced pluripotent stem cells (iPSCs).
• By application insights, the regenerative medicine segment is anticipated to grow over the forecast period owing to the transformative potential of induced pluripotent stem cells.

𝐔.𝐒. 𝐢𝐏𝐒𝐂 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• The cell culture segment holds a dominant revenue share within the workflow segment of the market due to its crucial role in the production and maintenance of induced pluripotent stem cells (iPSCs). Cell culture techniques are considered the foundation of iPSC research and development as they enable the expansion, maintenance, and differentiation of iPSCs into diverse cell types.

• In the U.S. iPSC market, the regenerative medicine segment is expected to experience significant growth in the coming years, primarily due to the remarkable therapeutic potential of induced pluripotent stem cells (iPSCs) in treating a diverse range of medical conditions.

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

𝐄-𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/e-pharma-market
𝐒𝐞𝐩𝐬𝐢𝐬 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭:
https://www.polarismarketresearch.com/industry-analysis/global-sepsis-diagnostics-market
𝐂𝐨𝐬𝐦𝐞𝐭𝐢𝐜 𝐒𝐮𝐫𝐠𝐞𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/cosmetic-surgery-market
𝐇𝐨𝐦𝐞 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/home-healthcare-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

Polaris Market Research
Phone: +1-929-297-9727
Email: sales@polarismarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.